A detailed history of Cibc Asset Management Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Cibc Asset Management Inc holds 8,771 shares of ALKS stock, worth $263,743. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,771
Previous 8,855 0.95%
Holding current value
$263,743
Previous $213,000 15.02%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$23.01 - $28.55 $1,932 - $2,398
-84 Reduced 0.95%
8,771 $245,000
Q2 2024

Aug 01, 2024

SELL
$23.21 - $27.24 $8,982 - $10,541
-387 Reduced 4.19%
8,855 $213,000
Q1 2024

May 09, 2024

SELL
$26.4 - $32.56 $1,742 - $2,148
-66 Reduced 0.71%
9,242 $250,000
Q4 2023

Feb 13, 2024

BUY
$23.37 - $28.68 $217,527 - $266,953
9,308 New
9,308 $258,000
Q2 2019

Aug 05, 2019

SELL
$21.47 - $37.33 $179,961 - $312,900
-8,382 Closed
0 $0
Q1 2019

May 06, 2019

BUY
$28.4 - $36.49 $25,844 - $33,205
910 Added 12.18%
8,382 $306,000
Q4 2018

Feb 12, 2019

SELL
$27.94 - $44.61 $1,983 - $3,167
-71 Reduced 0.94%
7,472 $220,000
Q3 2018

Nov 02, 2018

SELL
$38.6 - $46.12 $2,702 - $3,228
-70 Reduced 0.92%
7,543 $320,000
Q2 2018

Aug 09, 2018

BUY
$40.56 - $51.36 $17,359 - $21,982
428 Added 5.96%
7,613 $313,000
Q1 2018

Apr 30, 2018

SELL
$53.61 - $67.26 $5,468 - $6,860
-102 Reduced 1.4%
7,185 $416,000
Q4 2017

Feb 02, 2018

BUY
$47.69 - $55.39 $39,010 - $45,309
818 Added 12.64%
7,287 $399,000
Q3 2017

Nov 06, 2017

BUY
$49.16 - $54.45 $318,016 - $352,237
6,469
6,469 $329,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.94B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Cibc Asset Management Inc Portfolio

Follow Cibc Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Asset Management Inc with notifications on news.